Skip to main content

Advertisement

SpringerLink
Log in

News & Commentary

ICE and apoptosis

  • News and Commentary
  • Published:
Molecular Psychiatry Submit manuscript

Abstract

This issue features an article by Lynch, Shivers and colleagues (pages 227–238) which presents a novel, cell-permeable cysteine protease inhibitor, boc-aspartyl(OMe)-fluoromethylketone (boc-Asp-CH2F, abbreviated BAF). This inhibitor is an important new tool available to the research community and may represent a harbinger of a new class of chemicals useful in the treatment of human disease. In order to understand the value of BAF, we need to take a step back and examine the current concepts on the role of apoptosis in human disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Dept of Pharmacology, Loyola University Medical Center, Bldg 102, Rm 3634, 2160 South First Ave, Maywood, 60153, IL, USA

    B Wolozin

Authors
  1. B Wolozin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wolozin, B. ICE and apoptosis. Mol Psychiatry 2, 184–187 (1997). https://doi.org/10.1038/sj.mp.4000243

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.mp.4000243

  • Springer Nature Limited

Search

Navigation